Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation (Nasdaq: ABSI) is a clinical-stage biopharmaceutical and biotechnology company that frequently issues news related to its generative AI-driven drug discovery platform and internal pipeline of biologic therapeutics. News coverage for Absci often centers on developments in its lead AI-designed antibody programs, platform collaborations, and corporate updates that are relevant to investors and the broader life sciences community.
A major focus of recent Absci news is ABS-201™, an anti-prolactin receptor (PRLR) antibody being developed for androgenetic alopecia and investigated for endometriosis. Press releases have described preclinical human ex vivo data on hair growth, the design and initiation of the Phase 1/2a HEADLINE trial in androgenetic alopecia, and plans for Phase 2 development in endometriosis. Updates also highlight scientific advisory board appointments, key opinion leader seminars, and partnerships aimed at elevating patient perspectives in hair loss research.
Investors following ABSI news can also expect announcements on pipeline progress for programs such as ABS-101, ABS-301, and ABS-501, as well as drug creation partnerships with pharmaceutical, biotech, technology, and academic organizations. Absci has reported collaborations with cloud and hardware providers to support its AI Drug Creation platform, along with participation in healthcare and biotech investor conferences and major industry events.
This news feed aggregates Absci’s press releases and third-party coverage, including items on clinical trial milestones, scientific data presentations, financing and capital markets activity, and corporate governance changes. Readers interested in ABSI can use this page to monitor how Absci’s AI-enabled platform, internal therapeutic programs, and partnerships evolve over time and to track key events that may shape the company’s scientific and business trajectory.
Absci Corporation (Nasdaq: ABSI) has appointed Dan Rabinovitsj, a technology veteran and Meta Connectivity VP, to its Board of Directors. With over 30 years of experience in technology scaling and business model innovation, Rabinovitsj aims to enhance Absci’s generative AI-driven drug creation capabilities. His addition follows Dr. Andreas Busch's transition to Chief Innovation Officer. Rabinovitsj’s background includes key roles in major tech firms, which the CEO believes will be invaluable as Absci seeks to create biologics more efficiently.
Absci Corporation (Nasdaq: ABSI) announced participation in the Credit Suisse Annual Healthcare Conference to be held in Rancho Palos Verdes, CA, on November 10, at 9:10 a.m. PT. The event will feature a fireside chat with Absci management, which can be accessed via a live and archived webcast on their investor relations website. Absci focuses on protein drug creation, utilizing generative AI and biological data to advance therapeutic development.
Absci Corporation (Nasdaq: ABSI) has appointed Dr. Andreas Busch as Chief Innovation Officer, transitioning from the Board of Directors to the executive team. With extensive experience in R&D at major pharma companies, Dr. Busch has facilitated the development of over 10 FDA-approved drugs. His role will involve leading R&D and technical operations, enhancing Absci's drug creation capabilities through generative AI and high-throughput data technologies. The company aims to revolutionize drug discovery and improve access to effective therapeutics for patients.
Absci Corporation (Nasdaq: ABSI) announced its participation in the Morgan Stanley Annual Healthcare Conference in New York on September 14, 2022. The company will engage in a fireside chat scheduled for 4:05 PM ET. Interested parties can access a live and archived webcast via the company’s investor relations website. Absci focuses on drug and target discovery using deep learning AI and synthetic biology, aiming to enhance protein therapeutic potentials.
Absci Corporation (Nasdaq: ABSI) announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase, scheduled for August 31, 2022. The company will present in a fireside chat at 7:00 a.m. PT (10:00 a.m. ET). Interested parties can access the live and archived webcast on its investor relations website. Absci specializes in drug and target discovery using deep learning AI and synthetic biology, aiming to expand therapeutic proteins' potential through its Integrated Drug Creation™ Platform.
Absci Corporation (Nasdaq: ABSI) reported a strong performance in Q2 2022, signing ten Active Programs, exceeding its annual guidance of eight. Cash and equivalents stood at $206 million, down from $252.6 million at 2021's end. R&D expenses rose to $16.2 million, while SG&A expenses increased to $10.5 million. The net loss reduced to $28.7 million from $41.2 million year-over-year. A strategic reorganization aims to extend the cash runway into late 2025, focusing on AI-driven drug discovery. The company is projecting a net decrease in cash of approximately $110 million for 2022.
Absci Corporation (Nasdaq: ABSI) is set to participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference on August 9, 2022, at 3:00 p.m. PT. The event will feature a fireside chat with company management, accessible via a live and archived webcast on their investor relations website.
Absci is focused on drug and target discovery, leveraging deep learning AI and synthetic biology to enhance protein therapeutic potential. Their Integrated Drug Creation™ Platform enables efficient identification and development of novel biotherapeutics.
Absci Corporation (Nasdaq: ABSI) will participate virtually in the SVB Securities CybeRx event focusing on Big Data, A.I., and Machine Learning in Healthcare. The company is scheduled for the Drug R&D and Development panel on July 27, 2022, at 6:00 a.m. PT (9:00 a.m. ET). Absci is known for its innovative Integrated Drug Creation™ Platform, which leverages deep learning AI and synthetic biology to enhance protein therapeutic potential. The company aims to revolutionize drug discovery and development by creating next-generation protein-based drugs.
Absci Corporation (Nasdaq: ABSI) announced the hiring of two senior executives: Denise Dettore as Chief People Officer and Jack Gold as Chief Marketing Officer. Dettore brings 26 years of HR experience, including leadership roles in biotech and high-tech industries, while Gold has extensive marketing expertise from previous roles at Zymergen and Nike. Both leaders are expected to enhance Absci's growth and organizational culture as the company focuses on leveraging AI in drug discovery and advancing its brand.
Absci Corporation (Nasdaq: ABSI) announced a collaboration with an undisclosed stealth-mode biotech company, focusing on antibody-drug-conjugates (ADCs) for oncology. The partnership involves generating up to seven novel Bionic Antibodies using Absci’s Bionic Protein™ technology, which incorporates non-standard amino acids (nsAAs). This innovative approach aims to enhance the targeting and potency of ADCs while reducing toxicities. The financial terms remain undisclosed but include upfront payments, milestones, and royalties.